TABLE 3.
Demographic and clinical data of the validation cohort.
| Validation patients | Regression group (n = 36) | Non-regression group (n = 36) | p-value |
|---|---|---|---|
| Male/female | 22/14 | 22/14 | — |
| Age (y) | 43 ± 6.75 | 43 ± 8.75 | 0.894 |
| BMI | 23.75 ± 2.36 | 23.21 ± 2.62 | 0.397 |
| ALT (IU/L) | 40.74 ± 23.28 | 34.5 (25, 57.58) | 0.702 |
| AST (IU/L) | 30.5 (24, 51.25) | 36.50 (30, 53.13) | 0.213 |
| Alb (g/L) | 43.03 ± 5.46 | 41.85 ± 6.15 | 0.695 |
| TBIL (μmol/L) | 13.43 ± 6.86 | 11.3 (8.13, 19.14) | 0.724 |
| Cr (μmol/L) | 65.35 ± 16.95 | 68.25 ± 14.55 | 0.478 |
| WBC (×109/L) | 4.62 (3.41, 6.04) | 4.52 ± 1.63 | 0.444 |
| HGB (g/L) | 145 (126.5, 157.1) | 139.44 ± 18.23 | 0.608 |
| PLT (×109/L) | 121.83 ± 56.6 | 115.41 ± 57.15 | 0.665 |
| PT (s) | 13.32 ± 1.5 | 13.5 (12.4, 14) | 0.568 |
| TC (mmol/L) | 4.09 ± 0.99 | 4.21 ± 1.05 | 0.659 |
| TG (mmol/L) | 1.05 (0.82, 1.29) | 1.16 ± 0.49 | 0.534 |
| HDL-CH (mmol/L) | 1.38 ± 0.4 | 1.42 ± 0.41 | 0.735 |
| LDL-CH (mmol/L) | 2.39 ± 0.82 | 2.44 ± 0.79 | 0.808 |
| Blood glucose (mmol/L) | 5.01 ± 0.57 | 5.3 (4.56, 6.17) | 0.09 |
| AFP (ng/mL) | 12.46 ± 13.22 | 23.70 ± 59.55 | 0.082 |
| Positive HBeAg, n, % | 19 (52.7%) | 15 (41.5%) | 0.345 |
| Log10 HBV DNA (IU/mL) | 4.35 ± 1.79 | 4.98 ± 2 | 0.197 |
| Ishak score (n, %) | 0.471 | ||
| F5 | 23 (63.8%) | 20 (55.6%) | |
| F6 | 13 (36.1%) | 16 (44.4%) |
Annotations: BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Alb, Albumin; TBIL, total bilirubin; GGT, γ-glutamyl transpeptidase; ALP, alkaline phosphatase; Cr, Creatinine; WBC, white blood cell; HGB, hemoglobin; PLT, platelet count; PT, prothrombin time; TC, total cholesterol; TG, triglyceride;HDL-CH, High-density lipoprotein cholesterol; LDL-CH, Low-density lipoprotein cholesterol; AFP, alpha fetoprotein.